Overexpression of eEF2 protein was detected in 71.0% (22 of 31) of lung adenocarcinoma, 95.0% (19 of 20) of small-cell lung cancer, 73.3% (11 of 15) of esophageal cancer, 60.7% (17 of 28) of pancreatic cancer, 50.0% (4 of 8) of breast cancer, 75.0% (3 of 4) of prostate cancer, 52.4% (11 of 21) of HNSCC, 75.0% (12 of 16) of glioblastoma multiformes, and 94.0% (47 of 50) of NHL. The gene discussed is EEF2; the disease is pancreatic neoplasm.